证券代码：300685 证券简称：艾德生物 公告编号：2024-024 厦门艾德生物医药科技股份有限公司 第三届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第三届董事会第十八次会议于2024年4月22日在厦门市海沧区鼎山路39号公司 会议室以通讯和现场表决相结合的方式召开，会议应到董事9人，实到董事9人， 符合公司章程规定的法定人数。公司监事和高级管理人员列席了本次会议。本次 会议通知于2024年4月19日以电子邮件等形式发出，会议的通知和召开符合《公 司法》与《公司章程》的规定。本次会议由公司董事长LI-MOU ZHENG先生主 持。 二、董事会会议审议情况 1、审议通过《2024年第一季度报告》 表决结果：9票赞成，0票反对，0票弃权，本议案获表决通过。 2024年第一季度报告具体内容详见中国证监会指定的创业板信息披露网站。 本议案已经公司董事会审计委员会审议通过。 三、备查文件 2024 年 4 月 23 日 公司第三届董事会第十八 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a projected investment return exceeding 15% over the next 6-12 months [6][14]. Core Insights - The company achieved a revenue of 1.044 billion yuan in 2023, representing a year-on-year growth of 23.91%. The domestic market contributed 785 million yuan, growing by 23.65%, while the international market generated 258 million yuan, with a growth of 24.68%. The net profit attributable to shareholders was 261 million yuan, a slight decrease of 0.86%, but the net profit excluding non-recurring items increased by 52.21% to 239 million yuan [2][22]. - The company has accelerated its global expansion, establishing subsidiaries in Hong Kong, Singapore, and Canada, and forming partnerships with over 100 international distributors. It has localized teams in key overseas markets, enhancing its global footprint [8]. - The company has invested significantly in R&D, with 503 personnel and an R&D expenditure of approximately 203.22 million yuan, accounting for 19.47% of its revenue. It has obtained 26 Class III medical device registrations and 59 invention patents, showcasing its commitment to innovation [24]. Summary by Sections Financial Performance - In 2023, the company reported a revenue of 1.044 billion yuan, a 23.91% increase from the previous year. The domestic revenue was 785 million yuan, up 23.65%, while international revenue reached 258 million yuan, growing by 24.68%. The net profit attributable to shareholders was 261 million yuan, down 0.86%, but the net profit excluding non-recurring items rose by 52.21% to 239 million yuan [2][22]. Global Expansion - As of the end of 2023, the company has nearly 70 personnel in its international business and BD teams, collaborating with over 100 international distributors. It has established wholly-owned subsidiaries in Hong Kong, Singapore, and Canada, and a European logistics center in the Netherlands, while forming localized teams in Southeast Asia, the Middle East, Africa, and Latin America [8]. R&D and Innovation - The company has a strong focus on R&D, with 503 employees dedicated to this area and an investment of 203.22 million yuan, which is a 16.44% increase year-on-year. This investment represents 19.47% of its total revenue. The company has launched significant products, including the ADx-SEQ200 Plus high-throughput gene sequencer and the MSI test kit, which is the first pan-cancer immunotherapy companion diagnostic product approved in China [24].

Investment Rating - The investment rating for the company is "Accumulate" [1][3] - The previous rating was also "Accumulate" [1] - The target price has been adjusted to 24.82 from the previous 27.30 [1] Core Insights - The company's performance met expectations, highlighting compliance advantages in the domestic market, rapid growth in in-hospital reagent revenue, and swift international market expansion [1] - The company is expected to continue its rapid growth due to accelerated market access and an expanding network of pharmaceutical partnerships [1] - The company achieved a revenue of 1.044 billion yuan in 2023, representing a year-on-year increase of 23.91% [1] - The net profit attributable to shareholders for 2023 was 261 million yuan, with a significant increase of 121.68% year-on-year [1] Financial Summary - Revenue for 2023 was 1.044 billion yuan, with a net profit of 261 million yuan [1] - The company reported a non-net profit of 239 million yuan, reflecting a year-on-year growth of 52.21% [1] - The earnings per share (EPS) for 2024 and 2025 are forecasted at 0.73 yuan and 0.95 yuan respectively [1] - The company’s total market capitalization is 8,032 million yuan [1] Market Position and Growth - The company has a strong compliance advantage in the domestic market, with in-hospital testing reagent revenue growing over 40% year-on-year [1] - The international market is expanding rapidly, with international sales reaching 258 million yuan, a growth of 24.68% [1] - The company has established local teams in key overseas markets to accelerate market entry [1] Valuation Metrics - The company is valued at a PE ratio of 34X for 2024 [1] - The projected net profit for 2024 is 291 million yuan, with a growth rate of 7% [1] - The company’s return on equity (ROE) is projected to be 15.4% in 2024 [1]

表决结果：9票赞成，0票反对，0票弃权，本议案获表决通过。 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第三届董事会第十七次会议于2024年4月13日在厦门市海沧区鼎山路39号公司 会议室以通讯和现场表决相结合的方式召开，会议应到董事9人，实到董事9人， 符合公司章程规定的法定人数。公司监事和高级管理人员列席了本次会议。本次 会议通知于2024年4月3日以电子邮件等形式发出，会议的通知和召开符合《公 司法》与《公司章程》的规定。本次会议由公司董事长LI-MOU ZHENG先生主 持。 二、董事会会议审议情况 1、审议通过《2023年度总经理工作报告》 证券代码：300685 证券简称：艾德生物 公告编号：2024-017 厦门艾德生物医药科技股份有限公司 董事会听取了公司总经理所作的《2023年度总经理工作报告》，认为2023 年度公司经营管理层有效执行了董事会、股东大会的各项决议，较好地完成了 2023年度的经营目标。 详细内容请 ...

厦门艾德生物医药科技股份有限公司 董事会提名委员会议事规则 厦门艾德生物医药科技股份有限公司 董事会提名委员会议事规则 第一章 总则 第一条 为完善厦门艾德生物医药科技股份有限公司（以下简称"公司"）法人治理 结构，增强董事选举程序的科学性、民主性，优化董事会的组成人员结构，根据《中华 人民共和国公司法》《上市公司独立董事管理办法》《厦门艾德生物医药科技股份有限公 司章程》（以下简称"《公司章程》"）《厦门艾德生物医药科技股份有限公司独立董事工作 制度》（以下简称"《独立董事工作制度》"）及其他有关规定，公司特设立董事会提名委 员会，并由公司董事会制定本议事规则，规范其运作。 第二条 董事会提名委员会是董事会下设的专门工作机构，主要负责拟定公司董事、 高级管理人员的选择标准和程序，对董事、高级管理人员人选及其任职资格进行遴选、 审核。 第二章 人员组成 第三条 提名委员会委员由三名董事组成，其中独立董事占多数。 提名委员会委员由公司董事会选举产生，向董事会负责。 第四条 提名委员会设召集人一名，由独立董事担任，由全体委员选举产生。 提名委员会召集人负责召集和主持提名委员会会议，当召集人不能或无法履行职责 时， ...

厦门艾德生物医药科技股份有限公司 审计报告及财务报表 二○二三年度 厦门艾德生物医药科技股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-114 | 审计报告 信会师报字[2024]第 ZA11075 号 厦门艾德生物医药科技股份有限公司全体股东： 一、 审计意见 我们审计了厦门艾德生物医药科技股份有限公司（以下简称艾德 生物）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债 表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,043,506,694.32, representing a 23.91% increase compared to CNY 842,180,427.77 in 2022[22]. - The net profit attributable to shareholders for 2023 was CNY 261,484,433.37, a slight decrease of 0.86% from CNY 263,743,023.32 in the previous year[22]. - The net profit after deducting non-recurring gains and losses increased by 52.21% to CNY 238,952,550.49 from CNY 156,986,572.23 in 2022[22]. - The cash flow from operating activities for 2023 was CNY 298,715,870.41, showing a significant increase of 100.43% compared to CNY 149,036,792.06 in 2022[22]. - The total assets at the end of 2023 reached CNY 1,934,881,553.02, marking a 17.20% increase from CNY 1,650,924,910.62 at the end of 2022[22]. - The basic earnings per share for 2023 was CNY 0.66, a decrease of 1.49% from CNY 0.67 in 2022[22]. - The weighted average return on equity for 2023 was 16.33%, down from 18.42% in 2022[22]. - The company's revenue surpassed 1 billion yuan for the first time in 2023, with a year-on-year growth of 23.91%, and a net profit of over 230 million yuan, up 52.21% year-on-year[69]. Research and Development - The company emphasizes the importance of continuous R&D to maintain competitive advantage in the rapidly evolving in vitro diagnostics industry[5]. - The company has applied for over 80 invention patents, with 59 granted, highlighting its commitment to innovation in the medical device sector[37]. - The company’s R&D investment reached 203.22 million yuan in 2023, a year-on-year increase of 16.44%, accounting for 19.47% of total revenue[61]. - The company has maintained a high gross margin due to its competitive product advantages, but faces potential threats from increased market competition and rising costs[112]. - The company aims to maintain its innovation leadership in the tumor precision diagnosis sector by continuously exploring cutting-edge technologies and product transformations[107]. - The company has developed a comprehensive solution for tumor precision detection, covering sample processing, nucleic acid extraction, automated reporting, and data management systems[40]. Market and Product Development - The company is focusing on the development of LDT products, with a rich pipeline including HRD and HRR products for various cancers, aiming to meet clinical needs in precision oncology[35]. - The company is positioned to benefit from increasing demand for tumor gene testing driven by aging populations and rising cancer incidence rates[32]. - The company has independently developed and approved 26 types of tumor gene testing products in China, making it a leading enterprise in the industry with the most comprehensive product variety[41]. - The company has received III class medical device registration for multiple products, with some products being the only approved ones in China[41]. - The company has nearly 40 products that have received CE certification in the European Union, expanding its international market presence[49]. - The company has received regulatory approvals for over 20 products in Southeast Asia, further broadening its market access[50]. Compliance and Quality Management - The company emphasizes the importance of compliance and quality management in the tumor gene testing market, which is expected to grow due to regulatory improvements[34]. - The company has established independent third-party medical testing laboratories, enhancing its capabilities in molecular pathology and clinical testing services[51]. - The company emphasizes strict quality control and compliance with legal regulations in its medical testing laboratories, ensuring data traceability and reliability[52]. - The company has maintained effective internal control systems, ensuring compliance and operational efficiency[166]. - The company has implemented a comprehensive internal control system to ensure compliance with laws and regulations, enhancing governance and protecting investor interests[175]. Strategic Planning and Governance - The company has established a performance evaluation and incentive mechanism that aligns with its operational goals and development status[120]. - The company prioritizes transparent information disclosure and investor relations management to ensure all shareholders have equal access to information[120]. - The company has a clear asset ownership structure, with no assets being used or occupied by controlling shareholders or their other enterprises[124]. - The company has a well-established organizational structure, including independent governance bodies such as the shareholders' meeting, board of directors, and supervisory board[124]. - The company is committed to maintaining compliance with regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[153]. Employee Management and Development - The total number of employees at the end of the reporting period is 1,119, with 675 in the parent company and 444 in major subsidiaries[158]. - The employee composition includes 503 technical personnel, 378 sales personnel, and 105 production personnel[158]. - The company has established a comprehensive training development system to enhance employee skills and overall quality[160]. - The company has implemented a stock incentive plan, with the first grant of restricted stock scheduled for November 24, 2023[165]. - The total remuneration for directors, supervisors, and senior management amounted to CNY 793.51 million for the reporting period[148]. Social Responsibility and Sustainability - The company actively promotes a low-carbon and sustainable development strategy, adhering to national policies on carbon neutrality[176]. - The company has engaged in public welfare projects to raise awareness about cancer prevention and early diagnosis[177]. - The company respects and protects the legitimate rights and interests of stakeholders, promoting sustainable development[121]. Financial Management and Risks - The company plans to actively implement fundraising projects to quickly realize expected benefits, which are crucial for enhancing production capacity and maintaining technological advantages[183]. - The company will increase R&D investment to enhance its core competitiveness, including expanding existing R&D centers and improving product development mechanisms[183]. - The company aims to improve internal controls and management levels to ensure normal operations and reduce management risks[183]. - The company has committed to managing and using raised funds strictly according to regulations, ensuring funds are used for specific business needs[183].

证券代码：300685 证券简称：艾德生物 公告编号：2024-023 厦门艾德生物医药科技股份有限公司 关于召开 2023 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东大会届次：2023年度股东大会 2．股东大会的召集人：厦门艾德生物医药科技股份有限公司（以下简称"公 司"或"艾德生物"）董事会 3．会议召开的合法、合规性： 经公司第三届董事会第十七次会议审议通过，决定召开2023年度股东大会。 召集程序符合有关法律、法规、部门规章、规范性文件和《公司章程》的规定。 4．会议召开的日期、时间： （1）现场会议召开时间为：2024年5月13日（星期一）下午14:00 （2）网络投票时间为：2024年5月13日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2024年5 月13日9:15-9:25，9:30-11:30和13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为：2024年5月13日9:15-15:00。 5．会议的召开方式：本次股东大会采取现场投票和网络投票相结 ...

2023 年度会计师事务所履职情况评估报告及 审计委员会对会计师事务所履行监督职责情况报告 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗 潘序伦博士于1927年在上海创建，1986年复办，2010年成为全国首家完成改 制的特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟 先生。立信是国际会计网络BDO的成员所，长期从事证券服务业务，新证券法 实施前具有证券、期货业务许可证，具有H股审计资格，并已向美国公众公司 会计监督委员会（PCAOB）注册登记。 （二）聘任会计师事务所履行的程序 公司第三届董事会审计委员会第六次会议、第三届董事会第十次会议、第 三届监事会第九次会议及2022年度股东大会分别审议通过《关于续聘公司 2023年度审计机构的议案》，同意聘任立信为公司2023年度的审计机构。 二、2023 年度会计师事务所履职情况评价 立信按照中国注册会计师审计准则和其他相关执业规范的要求，对公司 2023年度财务报表进行了审计，出具了标准无保留意见审计报告，同时对公司 2023年度非经营性资金占用及其他关联资金往来情况执行了相关工作，并出具 了专项报告。 在审计过程中，立信 ...

为进一步完善公司的法人治理结构，根据 2023 年发布的《上市公司章程指引》《上市 公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件，结合公司 实际情况，拟对《公司章程》进行系统性修订和完善。 | 项、第（二）项规定的情形收购本公司股份的，应当 | （一）项、第（二）项规定的情形收购本公司股份 | | --- | --- | | 经股东大会决议；公司因本章程第二十三条第一款第 | 的，应当经股东大会决议；公司因本章程第二十四 | | （三）项、第（五）项、第（六）项规定的情形收购 | 条第一款第（三）项、第（五）项、第（六）项规 | | 本公司股份的，可以依照本章程的规定或者股东大会 | 定的情形收购本公司股份的，可以依照本章程的规 | | 的授权，经三分之二以上董事出席的董事会会议决议。 | 定，经三分之二以上董事出席的董事会会议决议。 | | 公司依照本章程第二十三条第一款规定收购本公 | 公司依照本章程第二十四条第一款规定收购 | | 司股份后，属于第（一）项情形的，应当自收购之日 | 本公司股份 ...